These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 8105925)

  • 1. Treatment and prevention of relapses of CAPD Pseudomonas peritonitis.
    Pasadakis P; Thodis E; Eftimimiadou A; Panagoutsos S; Papazoglou D; Kaliengidou M; Kartali S; Vargemezis V
    Adv Perit Dial; 1993; 9():206-10. PubMed ID: 8105925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudomonas peritonitis in CAPD patients: characteristics and outcome of treatment.
    Chan MK; Chan PC; Cheng IP; Chan CY; Ng WS
    Nephrol Dial Transplant; 1989; 4(9):814-7. PubMed ID: 2516614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of vancomycin plus tobramycin as antiperitonitis regimen for patients on CAPD.
    Vargemezis V; Thodis E; Pasadakis P; Martinis G; Kousta E
    Adv Perit Dial; 1990; 6():123-5. PubMed ID: 1982788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Pseudomonas infections in peritoneal dialysis patients.
    Taber TE; Hegeman TF; York SM; Kinney RA; Webb DH
    Perit Dial Int; 1991; 11(3):213-6. PubMed ID: 1912015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of CAPD peritonitis with clavulanate potentiated ticarcillin.
    Pasadakis P; Thodis E; Euthimiadou A; Panagoutsos S; Oustoglou E; Kartali S; Vargemezis V
    Adv Perit Dial; 1992; 8():238-41. PubMed ID: 1361796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudomonas peritonitis and continuous ambulatory peritoneal dialysis.
    Krothapalli R; Duffy WB; Lacke C; Payne W; Patel H; Perez V; Senekjian HO
    Arch Intern Med; 1982 Oct; 142(10):1862-3. PubMed ID: 6812523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Our protocol in the treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis].
    Kostić S; Ljuvenović S; Velicković R; Stefanović V; Raicević R; Cukuranović R; Veljković S; Djordjević V; Malobabić Z
    Srp Arh Celok Lek; 1996; 124 Suppl 1():149-51. PubMed ID: 9102884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of meropenem plus tobramycin followed by meropenem plus vancomycin for treating peritonitis in patients on continuous ambulatory peritoneal dialysis.
    Kobayashi K; Nakamoto H; Okada S; Hoshitani K; Uchida K; Arima H; Shoda J; Takane Y; Ikeda N; Sugahara S; Okada H; Suzuki H
    Adv Perit Dial; 2006; 22():65-8. PubMed ID: 16983942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of exit-site infections due to Xanthomonas in CAPD patients: a comparison with Pseudomonas infection.
    Dapena F; Selgas R; Garcia-Perea A; Del Peso G; Bajo MA; Fernandez Reyes MJ; Jimenez C; Sánchez C; Muñoz I; De Alvaro F
    Nephrol Dial Transplant; 1994; 9(12):1774-7. PubMed ID: 7708263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial intraperitoneal therapy for CAPD peritonitis: the Network 9 Peritonitis Study.
    Brier ME; Aronoff GR
    Adv Perit Dial; 1994; 10():141-3. PubMed ID: 7999812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal vancomycin and ceftazidime in the treatment of CAPD peritonitis.
    Gray HH; Goulding S; Eykyn SJ
    Clin Nephrol; 1985 Feb; 23(2):81-4. PubMed ID: 3886227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Transperitoneal resorption of cefotiam in CAPD patients with and without peritonitis].
    Thomae U; Koblinger S
    Med Klin (Munich); 1994 Sep; 89(9):464-8. PubMed ID: 7968880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of peritoneal dialysis-associated peritonitis with continuous versus intermittent vancomycin/teicoplanin and ceftazidime in children: preliminary results of a prospective randomized trial. Members of APN Arbeitsgemeinschaft Paidiatrische Nephrologie.
    Klaus G; Schaefer F; Müller-Wiefel D; Mehls O
    Adv Perit Dial; 1995; 11():296-301. PubMed ID: 8534728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of peritonitis in CAPD with ciprofloxacin: long-term experience.
    Pérez Fontán M; Rosales M; Rodríguez-Carmona A; García Falcón T; Adeva M; Fernández Rivera C; Moncalián J
    Adv Perit Dial; 1993; 9():211-4. PubMed ID: 8105927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of intraperitoneal urokinase for resistant bacterial peritonitis in continuous ambulatory peritoneal dialysis.
    Tong MK; Leung KT; Siu YP; Lee KF; Lee HK; Yung CY; Kwan TH; Au TC
    J Nephrol; 2005; 18(2):204-8. PubMed ID: 15931649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefazolin and netilmycin versus vancomycin and ceftazidime in the treatment of CAPD peritonitis.
    Gucek A; Bren AF; Hergouth V; Lindic J
    Adv Perit Dial; 1997; 13():218-20. PubMed ID: 9360685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of intraperitoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients.
    Gadallah MF; Tamayo A; Sandborn M; Ramdeen G; Moles K
    Adv Perit Dial; 2000; 16():233-6. PubMed ID: 11045301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imipenem versus netilmicin and vancomycin in the treatment of CAPD peritonitis.
    Merchant MR; Anwar N; Were A; Uttley L; Tooth JA; Gokal R
    Adv Perit Dial; 1992; 8():234-7. PubMed ID: 1361795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between peritonitis and exit site infections in CAPD.
    Eisele G; Bailie GR; Lomaestro B
    Adv Perit Dial; 1992; 8():227-9. PubMed ID: 1361793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.